S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

SNDX Syndax Pharmaceuticals Inc

15.98

1.57 (10.90%)

Feb 05 2025 - Closed

Delayed by 15 minutes

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Syndax Pharmaceuticals Charts.

Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Syndax Pharmaceuticals Charts.

Syndax Pharmaceuticals Inc News

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Tuesday 4 February 2025 (1 day ago) • PR Newswire (US)

Syndax Announces Participation in February Investor Conferences
Thursday 30 January 2025 (7 days ago) • PR Newswire (US)

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Wednesday 22 January 2025 (2 weeks ago) • Edgar (US Regulatory)

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
Wednesday 15 January 2025 (3 weeks ago) • PR Newswire (US)

Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
Monday 13 January 2025 (3 weeks ago) • PR Newswire (US)

Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm
Tuesday 7 January 2025 (4 weeks ago) • PR Newswire (US)

Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
Tuesday 7 January 2025 (4 weeks ago) • PR Newswire (US)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Friday 3 January 2025 (1 month ago) • PR Newswire (US)

Form 8-K - Current report
Friday 20 December 2024 (2 months ago) • Edgar (US Regulatory)

Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial
Monday 9 December 2024 (2 months ago) • PR Newswire (US)

Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
Saturday 7 December 2024 (2 months ago) • PR Newswire (US)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 6 December 2024 (2 months ago) • Edgar (US Regulatory)

More Syndax Pharmaceuticals Inc News Articles

Vontobel Financial Produ...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions